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We have investigated mechanisms that contribute to
reinforce the relationship between inflammation and
cancer. Secreted phospholipase A2 group IIA (sPLA2-
IIA) is a molecule relevant in inflammatory events and
has been proposed as a marker for some of these.
Previously, we reported the mitogenic properties of this
sPLA2 in the human astrocytoma cell line 1321N1.
Here, we go deeper into the mechanisms that link this
inflammatory protein with proliferation in one of the
most aggressive types of tumors. We found that phos-
phorylation of the extracellular regulated kinase (ERK)
was preceded by the activation of the small GTPase
Ras, and both failed to be activated by inhibiting
protein kinase C (PKC). Fractionation and immunofluor-
escence studies revealed translocation of PKC alpha,
delta, and epsilon to the membrane fraction upon stimu-
lation with sPLA2-IIA. Immunoprecipitation analysis
showed that sPLA2-IIA induces phosphorylation of the
epidermal growth factor receptor (EGFR) through a
PKC-dependent pathway. We found that phosphoryl-
ation of this receptor contributed to Ras and ERK acti-
vation and that inhibition of ERK, PKC, and EGFR
blocked the mitogenic response induced by sPLA2-IIA.
This study showed that sPLA2-IIA is able to bring into
play EGFR to trigger its signaling and that PKC leads
the distribution of resources. Interestingly, we found
that this is not a cell-specific response, because sPLA2-
IIA was also able to transactivate EGFR in MCF7
human breast cancer cells. Therefore, this mechanism
could contribute to worsen the prognosis of a tumor in
an inflammatory microenvironment. We also present
more links of the tumor chain possibly susceptible to
targeting.
Keywords: cancer, epidermal growth factor receptor,
inflammation, secreted phospholipase A2-IIA, signal
transduction.
A
lthough inflammation is part of the defense
response, paradoxically it can lead to important
health disorders. Since it was discovered in the
19th century, chronic inflammation has been proven to
be a risk factor for cancer (for review see refs 1,2),
both at the onset and as a prognostic marker. The
tumor microenvironment is importantly orchestrated
by inflammatory cells and mediators, which participate
in key processes, such as proliferation, survival, and
migration. Inflammatory cytokines, such as interleukin
(IL)-1, IL-6, and tumor necrosis factor-a, have been
found to be increased in patients with metastatic
cancer. This finding makes anti-inflammatory drugs, as
well as mechanisms triggered by proinflammatory
mediators, of great clinical interest in the potential
prevention and treatment of some tumors.
Secreted phospholipase A2 type IIA (sPLA2-IIA) is an
acute-phase protein expressed in response to a variety of
proinflammatory cytokines by a number of different
tissues and cell types. Increased sPLA2-IIA plasma
levels have been reported in patients with various acute
and chronic inflammatory conditions3,4 and are a
marker for some of these.5,6
sPLA2-IIA expression and activity are increased in
numerous cancers, including breast, pancreatic, skin,
liver, and prostate cancers (for review see ref. 7).
Several investigations have related this expression to
prognosis, for example, in human breast cancer.8,9
sPLA2-IIA is also a marker of metastasis in patients
with ovarian or gastrointestinal cancer,10 and in prostate
adenocarcinoma the expression level increases along
with the tumor grade.11 In mice, the sPLA2-IIA gene,
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Pla2g2a, has been identified as a susceptibility gene for
cancers of the small and large intestines, although its
role in this tumor type is still controversial.12 Also, sub-
cutaneous injection of cells overexpressing PLA2g2a
resulted in increased tumor size, and these cells were
found to be more infiltrative than controls.13 The impor-
tance of these findings has drawn a claim for sPLA2-IIA
and other PLA2 isoforms to be studied and considered as
possible targets for anticancer drugs.7 Thus, there is
interest in the mechanisms by which sPLA2-IIA influ-
ences the tumor, which could contribute to the design
of more effective chemotherapeutic approaches.
For decades, sPLA2-IIA has been considered relevant
in different pathologies owing to its capacity to release
lipid mediators. In recent years, sPLA2-IIA has also
been revealed as a signaling molecule itself, independent
of its catalytic activity,14,15 and able to trigger different
pathways resulting in opposing cellular responses, such
as proliferation15,16 and apoptosis.17 In previous
studies, we demonstrated that in the human astrocytoma
cell line 1321N1, sPLA2-IIA triggered signaling cascades
that involve members of the mitogen activated protein
kinase (MAPK) family, resulting in proliferation of the
astrocytoma cells.15
The astrocytoma capacity of growth and invasion is
closely correlated with the expression of cell surface
receptors that sense the signals present in the tumor
microenvironment. One of the receptors found overex-
pressed in this tumor and many others is the epidermal
growth factor receptor (EGFR).18 Also, overexpression
of other signaling elements that can lead to proliferation,
such as protein kinase C (PKC), has been reported and
related to malignant progression.19 Both EGFR and
PKC could have a role in the sPLA2-IIA–induced acti-
vation of extracellular regulated kinase (ERK) and mito-
genesis. Therefore, we proposed to more deeply
characterize the signaling machinery triggered by this
inflammatory mediator, which ultimately leads to cell
proliferation. This study may shed new light on the
general machinery that modulates cancer and/or
cancer risk, providing a better understanding of the lin-
kages between inflammation and cancer.
Materials and Methods
Reagents
A C127 mouse fibroblast cell line stably transfected with
the coding sequence of sPLA2-IIA from human placenta
was used as a source of human recombinant enzyme (cell
line kindly provided by Dr. Bereziat, France). sPLA2-IIA
was purified as described previously,20 and the dose for
all experiments was 1 mg/ml, as determined in previous
studies.21 Farnesyl transferase inhibitor (FTI) 227, ator-
vastatin, PD98059, GF109203X, and AG1478 were
fromCalbiochem. Radiolabeled thymidine and antirabbit
secondary HRP antibody were from GE Healthcare.
Antimouse secondary HRP antibody was from
Bio-Rad. Rabbit anti-ERK2 was from Zymed
Laboratories. Rabbit phospho-ERK1/2 (Thr202/
Tyr204), cytosolic PLA2 (cPLA2), and Ras were from
Cell Signaling Technology. Antihuman actin antibody,
antibodies against the different PKC isoforms (alpha,
delta, epsilon, and zeta), and phospho-EGFR (Tyr-1173)
antibody were all from Santa Cruz Biotechnology.
Antiphosphotyrosine antibody, clone 4G10, was from
Upstate (Millipore). EGFR antibody was a kind gift from
Dr. Pandiella (Salamanca, Spain). Both antirabbit and
antimouse FITC secondary antibodies, phorbol myristate
acetate (PMA), and other chemicals were from Sigma.
Cell Culture and Transfection
1321N1, MCF7, and Calu-3 cells were cultured at 378C
under a 5% CO2 atmosphere in DMEM (1321N1 and
MCF7) or RPMI (Calu-3) supplemented with 100 U/
mL penicillin and 100 mg/mL streptomycin, 2 mM
glutamine, and FCS (5% for 1321N1 and MCF7 cells
or 10% for Calu-3 cells). The 1321N1 cells were
transfected using Lipofectamine (Invitrogen):DNA
(ratio 1.2:0.4) 24 hours before the assay, and cells
were serum starved overnight.
Immunoblotting
Once cells reached semiconfluence, they were serum
starved overnight. After stimulation, cells were har-
vested directly in Laemmli-dithiothreitol (DTT)
loading buffer and boiled for 5 minutes. SDS-PAGE of
all protein samples was then performed using polyviny-
lidene difluoride membranes, followed by detection
using the GE ECL system.
Ras Activation Assay
Cells were seeded onto 100-mm plates, and when they
reached semiconfluence, they were left in serum-free
medium overnight. After stimulation with the agonists,
they were harvested in 750 mL of lysis buffer (50 mM
Tris pH 7.4, 200 mM NaCl, 5 mM MgCl2, 1% NP40,
15% glycerol, 10 mg/mL leupeptin, 5 mg/mL aprotinin,
1 mM phenylmethylsulfonyl fluoride (PMSF), 100 mM
orthovanadate). After clearing the lysates by centrifu-
gation, we incubated the supernatants with GST-RBD-
Raf-1 (kindly provided by Dr. J. L. Bos, UMC,
Utrecht, The Netherlands) for 20 minutes at 48C. After
coupling, the GTP-bound form of Ras was recovered
by centrifugation using GST beads and washed with a
lysis buffer. The samples were then boiled in Laemmli-
DTT buffer and analyzed by SDS-PAGE.
Cell Fractionation Assay
Membrane-enriched fractionswereobtainedafter permea-
bilization of the cells with saponin.22 Briefly, cells were
seeded onto 100-mm plates and harvested in 400 mL of
Buffer A (150 mM KCl, 2 mM MgCl2, 20 mM HEPES,
10% glycerol, pH 7.2, 1 mM DTT, 1 mM EGTA, 1 mM
EDTA, 1 mM sodium orthovanadate, 10 mM sodium flu-
oride, 1 mM PMSF, 10 mg/mL leupeptin, and 10 mg/mL
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aprotinin) containing 0.02% (w/v) saponin. After cen-
trifugation, the supernatants (cytosolic fraction) were sep-
arated and boiled for 5 minutes in Laemmli-DTT buffer.
Pellets (membrane fraction) were washed and resus-
pended in Buffer A containing Triton X-100 and then
boiled in Laemmli-DTT buffer.
Immunofluorescence
Cells were grown on glass coverslips, serum starved
overnight, and stimulated as indicated in each case.
After the cells were washed with PBS, they were fixed
and permeabilized with 4% PFA–0.1% Triton X-100
PBS and blocked with PBS 1% BSA. The cells were
then incubated at 48C overnight with the primary
antibody. Following washing, coverslips were incubated
with the secondary antibody for 1 hour; after thorough
washing, they were mounted with Vectashield mounting
medium for fluorescence (Vector Laboratories). Images
were captured with a Nikon Eclipse TS100 microscope
using a 20× or 40× objective lens.
EGFR Immunoprecipitation
Cell lysates were immunoprecipitated with 4 mL/mL
anti-EGFR antibody at 48C for 4 hours, as described
previously.23 The immune complex was recovered
using GammaBind G-Sepharose. After washing, the
beads were resuspended in Laemmli-DTT loading
buffer and subjected to SDS-PAGE. The extent of tyro-
sine phosphorylation of EGFR was determined by
immunoblotting with an antiphosphotyrosine antibody.
Measurement of DNA Synthesis Reinitiation
Quiescent cells were treated in serum-free DMEM for
24 hours with sPLA2-IIA after preincubation with
either the inhibitor or vehicle. Four hours before the
cells were harvested, 0.5 mCi/mL [3H]thymidine was
added to the medium. The incubation was then termi-
nated by washing with ice-cold 0.1 M MgCl2, and the
radioactivity incorporated into the trichloroacetic acid
precipitable fraction was measured.
Results
sPLA2-IIA Activation of Ras is Essential for Full
Activation of ERK
One of the best-known and well-described pathways
that leads to ERK activation results from the activation
of the small GTPase Ras. A pull-down assay, using a
fusion protein with the Ras-binding domain of Raf-1
(GST-RBD), showed a transient activation of the small
GTPase Ras after sPLA2-IIA incubation of 1321N1
cells (Fig. 1A). This activation was already visible after
2 minutes of stimulation and reached its peak between
5 and 10 minutes, which preceded the phosphorylation
previously found in ERK by sPLA2-IIA in 1321N1 cells.
We proved the participation of Ras in the phos-
phorylation of ERK by transfecting the cells with a
plasmid that encodes for Ras N17, a dominant negative
mutant for Ras. A gel shift of ERK showed that the acti-
vation obtained in Ras N17-transfected cells was clearly
lower than in mock-transfected cells (Fig. 1B). Either
inhibition of the farnesyl transferase or the availability
of its substrate would interfere.
Aware of the limits of dominant negative mutants and
transient transfection itself, since the wild-type form is
still functional, we further confirmed the Ras-ERK
relationship using a different approach related to Ras
processing. When newly synthesized, Ras GTPases are
soluble cytosolic proteins that undergo prenylation to
Fig. 1. Ras participation in sPLA2-IIA–induced phosphorylation of
ERK. (A) Serum-starved 1321N1 cells were stimulated with
sPLA2-IIA for the indicated times. RasGTP was determined using
the RBD pull-down assay (upper), and total lysates were also
incubated with anti-Ras antibody (lower). (B) Cells were
transfected with RasN17 and then serum starved and stimulated
with sPLA2-IIA for the indicated times. ERK2 phosphorylation was
checked by retardation on a Western blot. (C and D) Cells were
preincubated overnight with 10-mM FTI, 10-mM atorvastatin,
100-mM mevalonate, or vehicle and then stimulated with
sPLA2-IIA for 5 minutes. Western blots of the lysates were
incubated with phospho-ERK or Ras antibodies (upper band,
unprocessed Ras; lower band, processed Ras). The experiments
shown are representative of the results obtained in at least
3 trials for each condition.
M. Herna´ndez et al.: sPLA2-IIA transactivates EGFR
NEURO-ONCOLOGY 3
 at Centro de Inform
aciÃ³n y DocumentaciÃ³n CientÃ-fica on April 1, 2015
http://neuro-oncology.oxfordjournals.org/
D
ow
nloaded from
 
obtain the fully active enzyme. Either inhibition of the
farnesyl transferase or inhibition of its substrate avail-
ability would interfere in the isoprenylation of Ras
and, accordingly, in the processing to yield a functional
protein.24 We used 2 different compounds for this
purpose: FTI and atorvastatin, a permeable statin that
inhibits the 3-hydroxy-3-methylglutaryl coenzyme A
reductase and therefore inhibits synthesis of mevalonate
and the production of farnesyl pyrophosphate.
Preincubation with either of these compounds resulted
in an augmentation of unprocessed Ras in the cytosol,
unable to locate in the membrane (not shown).
Unprocessed Ras runs slower on SDS-PAGE, and both
the FTI- and atorvastatin-preincubated cells showed
more abundant unprocessed Ras after overnight treat-
ment (Fig. 1C). Phosphorylation of ERK by sPLA2-IIA
was clearly diminished in the presence of either atorvas-
tatin or FTI (Fig. 1C, upper panel), concordant with the
Ras N17 assay mentioned above. When mevalonate was
added to the culture medium at the same time as atorvas-
tatin, the effect of atorvastatin was bypassed (Fig. 1D),
while we found that in total protein the processed/
unprocessed Ras levels had returned to basal (Fig. 1C).
PKC is Upstream of Ras and ERK
Another pathway that could be activating ERK, and Ras
itself, comprises the PKC family. We preincubated
1321N1 cells with GF 109203X, a PKC inhibitor, for
30 minutes prior to stimulation with sPLA2-IIA. This
inhibitor showed a clear dose-dependent inhibition of
sPLA2-IIA–induced ERK phosphorylation (Fig. 2A).
We also found this inhibition downregulating
DAG-PKCs after overnight incubation with 1-mM
PMA (Fig. 2B), again confirming PKC participation in
ERK activation by sPLA2-IIA.
sPLA2-IIA activation of the cytosolic PLA2 (cPLA2) is
ERK dependent in this cell line15; therefore, we checked
whether PKC was, in turn, upstream of cPLA2. We incu-
bated 1321N1 cells with different doses of GF109203X
for 30 minutes prior to a 10-minute stimulation with
sPLA2-IIA. The phosphorylated form of cPLA2 runs
slower during electrophoresis, as shown in Fig. 2C,
and the PKC inhibitor also blocked the activation of
cPLA2 by sPLA2-IIA in a dose-dependent manner.
Next, we wondered whether Ras, which is necessary
for full activation of ERK, also needed PKC to be acti-
vated by sPLA2-IIA. For that purpose, we incubated the
cells with 1-mM PMA overnight and found that PMA
downregulation of DAG-dependent PKCs impeded Ras
activation by sPLA2-IIA (Fig. 2D). Thus, we can conclude
that PKC activation precedes Ras, thereby suggesting that
PKC activation is upstreamofRas and ERK in this system.
sPLA2-IIA Stimulation Induces PKC Translocation
to the Membrane
After activation, PKC translocates to the membrane to
find its substrate. We examined PKC alpha, delta,
epsilon, and zeta, and all expressed in 1321N1. After
stimulating the cells with sPLA2-IIA, we performed
fractionation studies. We found a quick and clear trans-
location of PKC alpha and epsilon to the membrane frac-
tion in the presence of sPLA2-IIA (Fig. 3A). A 5-minute
incubation with 1-mMPMAwas used as a classical posi-
tive control. We performed a detailed time course for
PKC delta (Fig. 3B) and found that translocation was
already visible 40 seconds after sPLA2-IIA was added
to the culture medium, and after 10 minutes it had
reverted to basal levels. PKC translocation induced by
sPLA2-IIA was not restricted to the outer membrane;
by immunofluorescence analysis, we found that, upon
stimulation, aggregates of PKC epsilon were formed in
Fig. 2. PKC participation in sPLA2-IIA–induced activation of ERK,
cPLA2, and Ras. (A and C) 1321N1 cells were incubated with the
indicated doses of GF109203X 30 minutes prior to stimulation
with sPLA2-IIA. Western blots of total lysates were incubated
with either phospho-ERK (upper A) or actin (lower A) antibodies
or cPLA2 antibody (C). (B) 1321N1 cells were incubated with
1-mM PMA overnight or with 1-mM GF109203X for 30 minutes,
prior to the addition of sPLA2-IIA for 5 minutes. Western blots of
the lysates were incubated either with phospho-ERK (upper) or
with actin antibody (lower). Samples shown belong to the same
experiment and were run simultaneously but not consecutively;
therefore, a lane represents the gap. (D) 1321N1 cells were
incubated with 1-mM PMA overnight and then with sPLA2-IIA
for the indicated times, and RasGTP was determined using the
RBD pull-down assay. The first lane shows a sample of total
lysate; the other lanes are Ras bound to the RBD, which
represents RasGTP. In all cases, cells were serum starved
overnight and the experiments shown are representative of the
results obtained in at least 3 trials for each condition.
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other membrane structures in the cell (in Fig. 3C, arrows
indicate some of these aggregates).
Therefore PKC alpha, delta, and epsilon underwent a
quick and transient translocation to the membrane,
whereas PKC zeta remained unaffected (not shown),
when 1321N1 cells were exposed to sPLA2-IIA.
sPLA2-IIA Transactivates EGFR, with the involvement
of PKC
Because PKCs can also activate Ras and ERK through
transactivation of other receptors and because we had
found tyrosine phosphorylation by sPLA2-IIA,
25 we
investigated the possibility of transactivation of the
EGFR upon sPLA2-IIA stimulation in 1321N1 cells.
Tyrphostin AG1478 (AG) is an inhibitor of EGFR, so
we preincubated 1321N1 astrocytoma cells with
AG1478 prior to stimulation with sPLA2-IIA. The dose
response of the inhibitor in a Ras pull-down assay
suggested a role for EGFR in sPLA2-IIA activation of
Ras, a partial inhibition of its activation (Fig. 4A). As
expected, ERK behaved the same way (Fig. 4B), and
only partial activation was achieved by sPLA2-IIA in
the presence of AG1478.
Fig. 3. PKC translocation to the membrane fraction. Serum-starved 1321N1 cells were stimulated with sPLA2-IIA or with 1-mM PMA
(positive control) for the indicated times, and the membrane-enriched fraction was separated by centrifugation as described in the
Methods section. SDS-PAGE was performed, and membranes were incubated with polyclonal antibodies against different PKC isoforms:
PKC alpha and epsilon (A) and PKC delta (B). (C) Cells were fixed after stimulation with sPLA2-IIA or vehicle for the indicated times and
incubated with a polyclonal antibody against PKC epsilon. Then an FITC secondary antibody was used, and the samples were analyzed
and photographed using a Nikon Eclipse TS100 microscope at ×40. The experiments shown are representative of the results obtained in
at least 3 trials for each condition.
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EGFR undergoes tyrosine phosphorylation when acti-
vated, sowe analyzed it byWestern blotting using an anti-
body that recognizes phosphorylated EGFR. Results of
this assay indicated that sPLA2-IIA induced a quick
EGFR phosphorylation, which was sustained for about
6 hours and then diminished (Fig. 4C), returning to
basal levels 12 hours after stimulation (not shown).
These results showed that the sPLA2-IIA signaling
cascade activates EGFR and that this transactivation
contributes to triggering Ras and ERK signaling.
We checked whether PKC was responsible for the
phosphorylation of EGFR by sPLA2-IIA in 1321N1
cells. We downregulated DAG-PKCs with a 1-mM
PMA treatment overnight and found that EGFR phos-
phorylation on tyrosine by sPLA2-IIA was considerably
diminished in PMA-preincubated cells compared with
cells preincubated with only vehicle (Fig. 4D).
Therefore, we show a role for PKC in this transactivation.
sPLA2-IIA–Induced Proliferation Depends on EGFR,
PKC, and ERK Activation
Proliferation is the cellular outcome after incubation of
1321N1 cells with sPLA2-IIA.
15 All the members of
the signaling cascades studied so far are closely related
to mitogenic pathways in several systems. To check
whether they were also involved in this system, assays
with [3H]thymidinewere performed in the absence or pres-
ence of their respective inhibitors: AG1478 for EGFR,
GF109203X for PKC, and PD098059 for MAPK kinase
(MEK) that consequently impedes activation of ERK.
We preincubated the cells with the indicated doses of
the inhibitors for 30 minutes prior to the addition of
sPLA2-IIA and found that the presence of each inhibitor
resulted in a clear and dramatic reduction of the mito-
genesis induced by sPLA2-IIA, as judged from the
amount of [3H]thymidine incorporated (Fig. 5A).
Therefore, the proliferation induced by sPLA2-IIA in
this human astrocytoma cell line is triggered by a
cascade depending on the activation of EGFR, ERK,
and PKC.
sPLA2-IIA Also Transactivates EGFR in MCF7 Human
Breast Cancer Cells
We wondered whether transactivation of this receptor
by sPLA2-IIA could be considered as a possible
Fig. 4. EGFR activation and participation in sPLA2-IIA–induced Ras
and ERK activation: role of PKC. Serum-starved 1321N1 cells were
preincubated with the inhibitors, when indicated, and stimulated
with sPLA2-IIA or vehicle for the indicated times. RasGTP was
analyzed after a 30-minute preincubation with AG1478 (A), ERK
phosphorylation was analyzed by Western blot with
phospho-ERK antibody in a time course after preincubation with
1-mM AG1478 for 30 minutes (B), EGFR phosphorylation was
also checked by Western blot with antiphospho-EGFR, (C) a time
course of sPLA2-IIA, and (D) a 5-minute stimulation with
sPLA2-IIA in the absence or presence of 1-mM PMA overnight.
The experiments shown are representative of the results obtained
in at least 3 trials for each condition.
Fig. 5. sPLA2-IIA–induced proliferation in 1321N1 cells and
sPLA2-IIA signaling induced in MCF7 cells. (A) Proliferation was
measured as described in the Methods section. Serum-starved
1321N1 cells were stimulated with sPLA2-IIA for 24 hours after
preincubation for 30 minutes with the indicated inhibitors (1-mM
AG1478, 1-mM GF109203X, or 25-mM PD98059) or vehicle.
[3H]Thymidine incorporated in sPLA2-IIA–stimulated cells was
taken as 100%, and the rest of the values were related to this.
Bars represent the means+S.E. of 3 independent experiments
performed in triplicate. (B and C) Serum-starved MCF7 cells were
stimulated with sPLA2-IIA for 5 minutes after an overnight
incubation with 1-mM PMA (B) or a 30-minute incubation with
AG1478 (C) at the indicated doses. Total lysates were subjected
to SDS-PAGE and incubated with phospho-EGFR (B) or
phospho-ERK (C).
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mechanism to induce mitogenesis by sPLA2-IIA in
other systems.
We performed our experiments in MCF7 cells, a
human breast cancer cell line that expresses EGFR.
Incubation with sPLA2-IIA induced the phosphorylation
of EGFR in MCF7 cells (Fig. 5B), as was found for the
astrocytoma cells. Similarly, downregulation of
DAG-PKCs by overnight incubation of the cells with
1-mM PMA diminished the level of transactivation.
Not only did this result parallel the findings of our
astrocytoma study, but we also found that sPLA2-IIA
induced phosphorylation of ERK. This phosphorylation
was not detected after preincubation of the cells with
different doses of the EGFR inhibitor AG1478
(Fig. 5C), suggesting a role for EGFR in the signaling
triggered by sPLA2-IIA in the human breast cancer cell
line MCF7 as well.
Next, we wondered whether the cellular outcome
after incubation with sPLA2-IIA would be similar to
that for the astrocytoma cell line. We performed DNA
synthesis reinitiation assays and found that
[3H]thymidine incorporation was also greater in the
presence of sPLA2-IIA than in the presence of a vehicle
(100% vs 18%), and preliminary data indicated that
sPLA2-IIA–induced proliferation was also both PKC
and ERK sensitive (from 100% to 46% and 70%,
respectively).
We also performed preliminary studies in the Calu-3
human lung adenocarcinoma cell line, which lacks
expression of the EGFR,26 and these studies found that
sPLA2-IIA was unable to induce a mitogenic response,
resulting in comparable values of [3H]thymidine incor-
porated in the presence or absence of the enzyme.
Likewise, no phosphorylation of ERK was found upon
exposure of Calu-3 cells to sPLA2-IIA, indicating that
it is unable to trigger this key signaling pathway.
Further investigation should follow in order to certify
a possible link between the level of EGFR expression
and the proliferative properties of sPLA2-IIA.
Discussion
Although there is plenty of evidence to ascertain that
inflammation can promote and influence cancer, the
cause of this relationship is not fully understood. In
this report, we showed how sPLA2-IIA, an acute-phase
protein present in inflammatory events and a wide
range of pathologies, including cancer, engages the
EGFR, which is frequently overexpressed in tumors, to
induce proliferation. We also showed how PKC, a key
molecule of many signaling cascades, plays a determin-
ing role. Because both EGFR and PKC are important sig-
naling elements in many tumor types, we consider this a
relevant finding in the event of inflammation, which is
frequently present in the tumor microenvironment.
We performed our studies in the 1321N1 human
astrocytoma cell line, in which incubation with
sPLA2-IIA induces proliferation.
15 We wondered how
sPLA2-IIA is able to elicit this response and the related
mechanisms.
ERK is involved in the regulation of cell proliferation,
survival, and differentiation; its aberrant regulation can
contribute to cancer, and therefore, all the members of
the Raf/MEK/ERK pathway have become classical
targets in the field.27 sPLA2-IIA induces phosphorylation
of ERK in 1321N1 astrocytoma cells15 and inhibition of
this pathway stops proliferation.28 ERK is, therefore, a
key element in sPLA2-IIA–induced mitogenesis;
consequently, we concentrated on unravelling the
upstream components that lead to ERK activation in
this system.
Ras proteins have been found to be overexpressed or
mutated in a wide variety of tumors, and they play a
pivotal role in the transduction of several growth or differ-
entiation stimuli (for review see refs 29,30). The switch of
the small GTPase Ras from GDP to GTP can trigger the
activation of the Raf/MEK/ERK cascade.31 We found
activation of Ras when sPLA2-IIA was present, and it is
necessary for full activation of ERK, as we showed by
transfecting a dominant negativemutant of Ras or inhibit-
ing Ras farnesylation with statins. In this situation, the
presence of mevalonate restores Ras conformation and
allows ERK full activation by sPLA2-IIA; therefore, we
discard statins effects, other than the inhibition of farnesy-
lation. Processingof other proteins canbealso inhibitedby
the blockage of farnesylation; related to proliferation, we
find the small GTPases Rheb (Ras homolog enriched in
brain) and RhoB32 and the centromeric proteins CENP-E
and CENP-F.33 Rheb has been described as regulating
B-Raf, inhibiting its activation,34 whereas RhoB has been
related to ERK but as an inhibitor.35 The
centromere-associated proteins CENP-E and CENP-F
are regulated duringmitosis, and the inhibition of farnesy-
lation results in accumulation of cells prior to meta-
phase.33 To our knowledge, there are no reports linking
these farnesylated proteins with ERK phosphorylation,
thereby reinforcing the role of Ras as an activator of
ERK in this system.
The activation of Ras as well as ERK itself can also be
achieved through the participation of members of the
extended PKC family, which have been linked to
cancer and represent a target for therapy.36 They could
act on the cascade leading to ERK activation at different
levels, activating Ras,37 Raf,38 or MEK39 or transacti-
vating other receptors that trigger the cascade Ras/
Raf/MEK/ERK.40
Several PKC isoforms were expressed and translo-
cated to the membrane upon sPLA2-IIA stimulation of
the astrocytoma cells: PKC alpha, PKC delta, and PKC
epsilon. In all cases, we found a very quick and transient
translocation. For PKC epsilon, we even found that
sPLA2-IIA induces translocation to cell compartments
other than the plasma membrane. PKC isoforms have
been described as presenting a particular pattern of acti-
vation depending on the stimuli, undergoing transloca-
tion to different cellular compartments41 for a yet
unknown purpose. The binding elements and precise
localization of PKC epsilon demand further investi-
gation. It has been stated that the expression and activity
of various PKC isoforms are increased in malignant
astrocytomas, suggesting that PKC activity contributes
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to tumor progression.19 In our system, inhibition of PKC
with GF109203X blocked proliferation; therefore, PKC
plays a determining role in the mitogenesis induced by
sPLA2-IIA. Also, the inhibition of ERK blocked prolifer-
ation in 1321N1, and we found a link between both
kinases: PKC is not only upstream of ERK and, as
expected, of the cytosolic PLA2, cPLA2 (downstream
effector of ERK15), but also of the activation of the
small GTPase Ras. These facts propose a cascade in
which PKC has a leading role and induces the activation
of the Ras/Raf/MEK/ERK canonical pathway; we
therefore considered the above-mentioned possibility
of transactivation of other receptors.
Murakami et al.42 proposed the involvement of
protein-tyrosine phosphorylation reactions in
sPLA2-mediated cell activation in view of inhibitors’
ability to block this reaction. In our system, sPLA2-IIA
also triggers a pathway dependent on tyrosine phos-
phorylation,25 supporting the possibility of transactiva-
tion of a growth factor receptor.
EGFR is one of themost important growth-stimulating
receptors in a great variety ofmalignant tumors.18Growth
factor receptors activate ERK by a canonical mechanism:
RTK-Shc-Grb2-Sos-Ras-Raf1-Mek-ERK.43 In this
report,we showed that sPLA2-IIA induces a quick and sus-
tained phosphorylation of EGFR. This activation is less
strong than that induced by its natural ligand, epidermal
growth factor, but similar in intensity, kinetics, and
profile to those found for EGFR transactivation in other
systems.44–46 We showed that this transactivation of the
EGFR is necessary for sPLA2-IIA–induced proliferation
in 1321N1 astrocytoma cells. The relevance of this mech-
anism becomes more apparent when we consider that the
most frequent genetic alteration associated with glioblas-
toma is amplification of the EGFR gene, which results in
overexpression of the receptor,47,48 believed to contribute
to the aggressive phenotype seen in these tumors.49
Because Ras is not a frequent mutation in glioblastoma,
the use of FTI inhibitors could be considered in the event
of activation, as in this situation, through the transactiva-
tion of the EGFR by sPLA2-IIA or any other factor in the
tumor microenvironment.
There are reports that state the relationship between
EGFR and PKC in both directions, EGFR-activating
PKC,50 and PKC-activating EGFR,40 as we find in this
system. PKC can induce activation of EGFR by several
mechanisms: ligand independent, through the activation
of Src by a GPCR, or ligand dependent, by activating
metalloproteinases, responsible for the release of extra-
cellular membrane-bound epidermal growth factor–
like ligands.51,52
How sPLA2-IIA is able to trigger all these pathways at
the membrane level remains unknown. The role of this
enzyme has been classically attributed to its catalytic
activity, because it releases bioactive lipids, such as ara-
chidonic acid, platelet-activation factor, and lysopho-
sphatidic acid.53 In previous studies, we had shown
that LPA is able to induce coupling of PLC to the recep-
tor, but it does not modify the phosphorylation status of
EGFR on its own in 1321N1 cells,23 either discarding
LPA or stimulating the search of a signaling partner
for LPA to accomplish the task. Nevertheless, when
that study took place, we could not find sPLA2-IIA
metabolites being released. Perhaps this finding should
be revisited using the newer technologies available,
even though sPLA2-IIA catalytic activity towards the
cell membrane is apparently restricted to bacteria and
modified eukaryotic membranes.53
On the other hand, the time course of EGFR phos-
phorylation shows an immediate response, discarding
prostaglandins as the inducers of EGFR transactivation,
as indicated in other reports.54 It is precisely the
immediateness of the response that leaves the direct inter-
actionof sPLA2-IIAwithamembrane structure as themost
plausible mechanism to trigger the signaling cascade of
concern. Heparan sulfate proteoglycans (glypican,
decorin, biglycan,M-type, N-type, or mannose receptors)
are claimed to be binding motifs for sPLA2-IIA.
55
Interestingly, a recent report has shown sPLA2-IIA induc-
tion of a mitogenic response linked to integrin engage-
ment.16 The interaction of sPLA2-IIA with a specific
receptor is also feasible, but not with those described so
far, because the M-type sPLA2 receptor is not expressed
in these cells and sPLA2-IIA has low affinity for the
N-type receptor.55 The search for the binding partner of
sPLA2-IIA, able to trigger the signaling cascades in these
cells, is the subject of future investigations.
In this study, we identified key elements (PKC and
EGFR) of the signaling cascade of sPLA2-IIA that lead
to proliferation in astrocytoma cells, since inhibition of
any of them blocks this cellular response. As noted in
the introduction, sPLA2-IIA is present in a wide range
of tumors of different origin. In breast cancer, it is
now upgraded to the status of a prognostic marker,8,9
and also in MCF7 we find that sPLA2-IIA transactivates
EGFR in a PKC-dependent manner. Again, sPLA2-IIA
induces proliferation in these cells, which is abrogated
by inhibition of PKC and ERK, conferring on EGFR a
responsibility in the activation of ERK.
Regardless of evident cell-line differences, sPLA2-IIA
triggers a similar cascade that results in a mitogenic
response through the transactivation of EGFR. Further
work could determine whether sPLA2-IIA mitogenic
potential directly depends on the EGFR expression (pre-
liminary work has shown that sPLA2-IIA is unable to
induce proliferation in a human cell line that lacks
EGFR) and also whether we are here presented with a
general mechanism to be taken into consideration in
tumors where sPLA2-IIA could be expressed due to an
inflammatory environment. Inflammation and EGFR
overexpression could occur in tandem to promote pro-
liferation and worsen the prognosis, not only at the
onset or development of the tumor. The resistance of
some tumors to radiotherapy has been related to a
higher expression of EGFR.56 The microenvironment
of the tumor could be playing a role in this event
because inflammation markers are found in patients
receiving radiotherapy.57
The value of EGFR as a prognostic marker in gliomas
is still under debate. Some studies point to differences
regarding other factors,58 which might suggest consider-
ing additional factors not strictly confined to the plasma
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membrane. Treatments for cancer could possibly be
made more effective by taking into account the charac-
teristics of not only the tumor itself but also its microen-
vironment at each stage.
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